Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Yuki MizunoAtsushi KudoTakumi AkashiKeiichi AkahoshiToshiro OguraKosuke OgawaHiroaki OnoYusuke MitsunoriDaisuke BanShinji TanakaUkihide TateishiMinoru TanabePublished in: Journal of cancer research and clinical oncology (2018)
Our results indicate that sunitinib is as effective for NET-G3 as for NET-G1/2.